Def Leppard Guitarist Vivian Campbell in Remission from Hodgkin's
Def Leppard guitarist Vivian Campbell, who had been undergoing treatment for Hodgkin's lymphoma, announced on his Facebook page that after several months of treatment he has been declared in remission by his doctors.
The musician first revealed that he had been diagnosed with Hodgkin's in June, two months after he began receiving treatment.
Campbell announces remission
On his Facebook page he wrote:
For anyone who gives a toss, after doing another PET scan and all the other follow up tests, then getting a second opinion etc., I'm officially in remission from Hodgies. That's the good news. The bad news is: I no longer have an excuse to not go to the gym.
A month ago, Campbell released a video on YouTube talking about his experience with Hodgkin's.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
